Navigation Links
Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
Date:2/11/2008

FREDERICK, Md., Feb. 11 /PRNewswire/ -- Cancer research pioneer Michael G. Hanna Jr. Ph.D., also Vaccinogen, Inc.'s Founder, Chairman and CEO has acquired the rights to OncoVAX(R), a vaccine with the potential to prevent colon cancer from recurring in many patients.

"This agreement represents a major step forward in defeating cancer by increasing the body's immunity to it," said Dr. Hanna, who has been working on cancer vaccines for more than 30 years.

In the agreement, Vaccinogen obtained exclusive license to OncoVAX(R) Active Specific Immunotherapy as well as an important component of the product TICE BCG. The vaccine is made from the patients' own tumor and is injected back into the patient to effect an immune response against recurrence of that cancer.

The FDA views Stage II colon cancer as an unmet medical need. When colon cancer recurs after surgery it is frequently fatal. OncoVAX(R) prevents that recurrence and thereby reduces recurrence and deaths by over 50%. Vaccinogen is currently preparing to commercialize the vaccine in Switzerland.

About OncoVAX(R)

OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases. Immune stimulation should be able to create a population of white blood cells that can kill tumor cells wherever they arise in the body, years after surgical removal of the original tumor.

Vaccinogen's scientists prepare a vaccine from the patient's own tumor. The cells are dissociated, irradiated to make them non-tumorigenic and administered to the patient by three weekly injections, starting four weeks after surgery. A booster vaccination is administered six months later.

About Vaccinogen

Vaccinogen is a biopharmaceutical company developing and commercializing cancer vaccines and other immunotherapeutic products. Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune and anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for the production of OncoVAX(R) vaccine.
http://www.vaccinogeninc.com

Contact:

Andrew L. Tussing

Vaccinogen

atussing@vaccinogeninc.com

301-668-8400


'/>"/>
SOURCE Vaccinogen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Cryostat Market is poised ... decade to reach approximately $3.5 billion by 2025. This ... given segments on global as well as regional levels presented in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Technique, Repair Procedure By Technique, By Region, By Country (2016-2021)" ... ... at a CAGR of 13.35% during 2016-2021 The strong ... growth in population with heart disease and rising advances in minimally ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The law ... White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined ... clerk for the firm, will concentrate her practice in elder law, Medicaid planning and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through ... a devotional journal chronicling the writer’s path toward true communion with God. “Finding ... God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, ... Broadway Avenue, will be an educational and exciting program providing busy clinicians and ... of chronic pain. , Oklahoma is in a healthcare crisis. The state ranks ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):